Search

MRx-4DP0004

MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.

Elvucitabine

Anti-SARS-CoV-2 IgY

[L27381] To create these antibodies, chickens are injected in the chest with the spike protein, which is the surface protein of SARS-CoV-2; this results in an immune response mounted by the chickens towards … These antibodies are currently being investigated against COVID-19 in the trial NCT04567810 (Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV

Reposal

Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.

Human interleukin-6

Human interleukin-6 is under investigation in clinical trial NCT03170245 (Adiponectin, IL-6 and hsC-RP in Relation to Carotid Intima-media Thickness in B-thalassemia Patients).

NV1020

NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.

Zaltoprofen

A non-steroidal anti-inflammatory drug approved for use in Japan in 1993.

AGS-004

This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment.

ARC183

The key advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life, giving it the potential to be an ideal agent for medical procedures that require rapid

PF-5212372

PF-5212372 is under investigation in clinical trial NCT02795832 (A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis).